IKT
NASDAQ · Biotechnology
Inhibikase Therapeutics Inc
$1.80
+0.12 (+7.14%)
Open$1.73
Previous Close$1.68
Day High$1.80
Day Low$1.70
52W High$2.46
52W Low$1.33
Volume—
Avg Volume2.36M
Market Cap197.67M
P/E Ratio—
EPS$-1.15
SectorBiotechnology
Analyst Ratings
Strong Buy
11 analysts
Price Target
+1,456.1% upside
Current
$1.80
$1.80
Target
$28.01
$28.01
$19.41
$28.01 avg
$39.32
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 78.22M | 74.95M | 61.90M |
| Net Income | 4.38M | 5.16M | 3.75M |
| Profit Margin | 5.6% | 6.9% | 6.1% |
| EBITDA | 7.32M | 7.08M | 6.90M |
| Free Cash Flow | 4.21M | 5.04M | 4.89M |
| Rev Growth | +8.7% | +15.3% | -5.1% |
| Debt/Equity | 0.35 | 0.45 | 0.33 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $214.98 | -1.15% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.28 | +0.41% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $140.30 | +0.67% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $447.26 | +0.16% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $777.25 | +0.60% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.73 | -0.65% | 139.7 | 43.84B |